Tocqueville Asset Management L.P. Sells 166,090 Shares of Pfizer Inc. (NYSE:PFE)

Tocqueville Asset Management L.P. decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 12.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,211,335 shares of the biopharmaceutical company’s stock after selling 166,090 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Pfizer were worth $32,137,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after acquiring an additional 12,864,343 shares during the period. Nordea Investment Management AB grew its holdings in shares of Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after purchasing an additional 1,080,822 shares in the last quarter. Parsons Capital Management Inc. RI increased its position in shares of Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after purchasing an additional 159,984 shares during the period. Parnassus Investments LLC raised its stake in shares of Pfizer by 3.7% in the third quarter. Parnassus Investments LLC now owns 4,390,705 shares of the biopharmaceutical company’s stock valued at $127,067,000 after purchasing an additional 156,894 shares in the last quarter. Finally, TrinityPoint Wealth LLC lifted its position in Pfizer by 85.5% in the third quarter. TrinityPoint Wealth LLC now owns 191,544 shares of the biopharmaceutical company’s stock worth $5,543,000 after purchasing an additional 88,258 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of a number of recent research reports. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Up 1.3 %

Shares of PFE opened at $26.07 on Tuesday. The stock’s fifty day simple moving average is $26.22 and its 200-day simple moving average is $27.10. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $147.72 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the firm earned $0.10 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.